SCHEMBL5012192

SCHEMBL5012192

O=C(NCc1cccc(C(F)(F)F)c1)c1cc(NC(=O)c2cc(F)c(F)cc2Cl)[nH]n1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.55
HPGD P15428 1/20 0.55
HSP90AA1 P07900 1/20 0.50
HSP90AB1 P08238 1/20 0.50
MEN1 O00255 1/20 0.50
PLA2G1B P04054 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
GAA P10253 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
RXFP1 Q9HBX9 1/20 0.46
CCR1 P32246 8/20 0.46
MLYCD O95822 1/20 0.46
PPARG P37231 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5010420 0.89 PPARG (0.47) LMNAHPGDGAAPPARG
SCHEMBL5013675 0.88 PPARG (0.48) MEN1KMT2APPARG
SCHEMBL5012134 0.88 PPARG (0.48) LMNAHPGDMEN1KMT2ACCR1
SCHEMBL5010405 0.87 PPARG (0.59) HSP90AA1HSP90AB1PPARG
SCHEMBL5010635 0.87 PPARG (0.47) MEN1KMT2APPARG
SCHEMBL5010362 0.87 PPARG (0.50) LMNAHPGDGAAPPARG
SCHEMBL5010462 0.86 PPARG (0.48) MEN1KMT2APPARG
SCHEMBL14587707 0.86 PPARG (0.51) PPARG
SCHEMBL5012182 0.85 PPARG (0.56) PPARG
SCHEMBL5010715 0.84 PPARG (0.49) LMNAGAAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL LMNA 2123/4885HPGD 3765/4885HSP90AA1 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.